# Evaluate the Efficacy and Safety of HIF-PHI for the Treatment of Anemia and Risks of Cardiovascular and Cerebrovascular Events in ESRD Newly Initiated Dialysis Patients

> **NCT04134026** · PHASE4 · UNKNOWN · sponsor: **Second Xiangya Hospital of Central South University** · enrollment: 400 (estimated)

## Conditions studied

- Anemia in Incident Dialysis Patients

## Interventions

- **DRUG:** HIF-PHI
- **DRUG:** Epoetin Alfa

## Key facts

- **NCT ID:** NCT04134026
- **Lead sponsor:** Second Xiangya Hospital of Central South University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-20
- **Primary completion:** 2023-10-19
- **Final completion:** 2024-10-19
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2021-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04134026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04134026, "Evaluate the Efficacy and Safety of HIF-PHI for the Treatment of Anemia and Risks of Cardiovascular and Cerebrovascular Events in ESRD Newly Initiated Dialysis Patients". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT04134026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*